CVS Health stock: Cantor Fitzgerald keeps a USD 110.00 target for CVS Health stock

Published on 10/21/2026 at 17:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CVS Health's results are due November 4, 2026. CVS Health stock costs EUR 83.68 on October 21, 2026, minus 0.38 percent versus the Xetra close.

Analyst target and reporting date

Cantor Fitzgerald reiterated a USD 110.00 target on October 9, 2026.
CVS Health's third-quarter results are scheduled for November 4, 2026.
CVS Health stock costs EUR 83.68 at Lang & Schwarz on October 21, 2026 at 5:13 p.m. CEST, minus 0.38 percent versus the EUR 84.00 Xetra close and 14.97 percent below its USD 110.68 52-week high.

Isometrische 3D-Illustration der Gesundheitsversorgungskette von Produktion über Apotheke bis Patient — CVS Health Corp. isometrisches 3D-Diagramm der Wertschöpfungskette von Pharma bis Patient, ISIN US1266501006, Illustration mit AI erstellt.

CVS Health Corp. (ISIN US1266501006) has a USD 110.00 price target from Cantor Fitzgerald, which reiterated its Overweight rating on October 9, 2026, according to Investing.com. The target is 16.88 percent above the USD 94.11 Nasdaq price at 11:23 a.m. ET on October 21, 2026. CVS Health was trading at EUR 83.68 at Lang & Schwarz on October 21, 2026 at 5:13 p.m. CEST, minus 0.38 percent versus the Xetra close of October 20, 2026 at EUR 84.00.

Cantor keeps USD 110.00 target

The Cantor view leaves a measurable gap between the US-listed share price and the analyst target. The USD 110.00 objective stands 16.88 percent above the USD 94.11 Nasdaq price, while the Overweight rating was reiterated on October 9, 2026.

What does the price position show?

CVS Health's Nasdaq price of USD 94.11 sat 14.97 percent below the USD 110.68 52-week high and 35.39 percent above the USD 69.51 low on October 21, 2026. Trading volume was 1,517,676 shares at 11:23 a.m. ET, compared with an average volume of 8,062,150 shares.

Results date and operating scale

CVS Health will discuss third-quarter 2026 results on November 4, 2026, at 8:00 a.m. ET, the company said in an October 5, 2026 release linked from CVS Health. As of June 30, 2026, the company had approximately 9,000 retail pharmacies, more than 1,000 walk-in and primary care clinics, about 87 million pharmacy-benefit members and an estimated 37 million health-insurance customers.

Comparison with peers

CVS Health Corp.: minus 0.38 percent versus the Xetra close, P/E 24.89, market capitalization EUR 110.5 billion.

UnitedHealth Group: minus 0.66 percent on the NYSE, P/E 23.75, market capitalization USD 373.9 billion.

Humana: plus 0.07 percent on the NYSE, P/E 40.49, market capitalization USD 51.4 billion.

CVS Health stock after the Xetra session

For investors, the key near-term test is whether the November 4 results add support to the USD 110.00 target or narrow the valuation gap. CVS Health stock was trading at EUR 83.68 at Lang & Schwarz on October 21, 2026 at 5:13 p.m. CEST, minus 0.38 percent versus the Xetra close of October 20, 2026 at EUR 84.00. The further course of trading is shown by the continuously updated real-time quote of CVS Health stock.